Thromboelastography During Surgery for Malignant Pleural Mesothelioma

Status Recruiting

Clinical Trial Summary

Surgery for malignant pleural mesothelioma is complex and prolonged, and may involve significant blood loss with considerable blood and product transfusion. Thromboelastography (TEG) is a global assay of coagulation that uses whole blood to produce a tracing that records kinetic changes in clot formation. This study aims provide a better understanding of the coagulation profile of these patients, and will form the basis of a TEG-based transfusion algorithm for future surgeries for mesothelioma.

Clinical Trial Description

Thromboelastography can provide more in-depth and quicker analysis of the complex coagulation processes during surgery ;

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01912547
Study type	Observational
Source	Brigham and Women's Hospital
Contact
Status	Recruiting
Phase	Phase 0
Start date	September 2013
Completion date	December 2015

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT01950572` - Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Terminated	`NCT01624090` - Mithramycin for Lung, Esophagus, and Other Chest Cancers	Phase 2
Active, not recruiting	`NCT04242199` - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors	Phase 1
Recruiting	`NCT05415098` - Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas	Phase 1
Completed	`NCT03652077` - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies	Phase 1
Recruiting	`NCT06057935` - A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma	Phase 2
Terminated	`NCT02838745` - Study of Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy With Pemetrexed and Cisplatin for MPM	Phase 1
Terminated	`NCT02628535` - Safety Study of MGD009 in B7-H3-expressing Tumors	Phase 1
Completed	`NCT01521325` - A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers	Phase 1
Recruiting	`NCT02073500` - Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies
Recruiting	`NCT00996385` - Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma	Phase 2
Completed	`NCT02467426` - Isolated Thoracic Perfusion (ITP-F) for MPM	Phase 2
Completed	`NCT00407459` - Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma	Phase 2
Completed	`NCT00787410` - An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma	Phase 2
Terminated	`NCT01907100` - Nintedanib (BIBF 1120) in Mesothelioma	Phase 2/Phase 3
Completed	`NCT04056026` - A Single Dose FMT Infusion as an Adjunct to Keytruda for Metastatic Mesothelioma	Early Phase 1
Completed	`NCT02903914` - Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors	Phase 1/Phase 2
Terminated	`NCT03319537` - Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma	Phase 1/Phase 2
Terminated	`NCT03685591` - PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors	Phase 1
Recruiting	`NCT03683680` - Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers	N/A